Glucagon-Like Peptide-1 Receptor Agonists Reduce Surgeries and Hospitalizations in Hidradenitis Suppurativa: A Multicenter TriNetX Cohort Study.

BACKGROUND

Hidradenitis suppurativa is a chronic inflammatory skin condition frequently associated with type 2 diabetes mellitus and obesity. Glucagon-like peptide-1 receptor agonists have emerged as promising agents for managing type 2 diabetes mellitus due to their potent effects on glycemic control and weight reduction. Recent evidence suggests that glucagon-like peptide-1 receptor agonists may also possess anti-inflammatory properties, potentially making them effective in treating inflammatory conditions, such as hidradenitis suppurativa.

OBJECTIVE

To determine if glucagon-like peptide-1 receptor agonists reduce surgeries and hospitalizations in patients with hidradenitis suppurativa.

METHODS

We utilized the TriNetX platform to evaluate the rate of surgical abscess repairs performed and hospitalizations in a propensity score-matched cohort of patients with hidradenitis suppurativa who were prescribed glucagon-like peptide-1 receptor agonists.

RESULTS

Our analysis revealed that patients prescribed glucagon-like peptide-1 receptor agonists had significantly lower rates of surgeries with a HR of 0.35 (95% CI: 0.25, 0.50) and hospitalizations with a HR of 0.87 (95% CI: 0.82, 0.92) compared to a control cohort of patients who did not receive glucagon-like peptide-1 receptor agonists.

CONCLUSIONS

Glucagon-like peptide-1 receptor agonists reduce surgeries and hospitalizations in hidradenitis suppurativa, demonstrating their potential therapeutic value in dermatology patient care.